Effect of hemodialysis on hepatic cytochrome P450 functional expression

Journal of Pharmacological Sciences

Volumn 108, Issue 2, 2008, Pages 157-163

  Michaud, Josée ^a,b   Nolin, Thomas D ^c,d   Naud, Judith ^a,b   Dani, Mélina ^a,b   Lafrance, Jean Philippe ^a   Leblond, Francois A ^c,d   Himmelfarb, Jonathan ^c,d   Pichette, Vincent ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAINE MEDICAL CENTER   (United States)

^d Maine Medical Center Research Institute   (United States)

Author keywords

Cytochrome P450; Drug metabolism; End stage renal disease; Gene expression; Hemodialysis

Indexed keywords

ANDROGRAPHOLIDE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2C; CYTOCHROME P450 3A; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER ENZYME; MESSENGER RNA;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CELL CULTURE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SERUM; UREMIA;

EID: 55549146147     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08042FP     Document Type: Article

References (20)

1. Michaud J, Dubé P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067-1077.
2. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124-128.
3. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109:1-11.
4. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906-925.
5. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317-1320.
6. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326-332.
7. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039-1046.
8. Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239-1246.
9. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475-477.
10. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427-434.
11. Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54:612-620.
12. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17:2363-2367.
13. Michaud J, Naud J, Chouinard J, Desy F, Leblond FA, Desbiens K. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2006;17:3041-3048.
14. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem. 2001;276:39638-39644.
15. Michaud J, Leblond FA, Naud J, Boisvert C, Desbiens K, Nicoll-Griffith DA, et al. Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods. 2007;55:209-213.
16. Guillen C, Martinez P, de Gortazar AR, Martinez ME, Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by nuclear factor-kappa B activation in osteoblastic cells. J Biol Chem. 2002;277:28109-28117.
17. Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther. 1985;233:277-284.
18. Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002;25:1077-1083.
19. Taburet AM, Vincent I, Perello L, Coret B, Baune B, Furlan V. Impairment of drug biotransformation in renal disease an in vitro model. Clin Pharmacol Ther. 1996;59:136.
20. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559-1564.